• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


Continued f/u of the premarket cohort

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Completed
Application Number P130009 S034/ PAS001
Date Current Protocol Accepted 11/04/2019
Study Name Continued f/u of the premarket cohort
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source Sponsor Registry
Comparison Group No Control
Analysis Type Descriptive
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Design Description Continued follow-up of premarket cohorts. The objective of this study is to characterize the cumulative clinical outcomes of all subjects at discharge or 7 days, whichever comes first, 30 days, 1 year, and annually thereafter through 5 years post procedure.
Study Population Description The study will consist of all living subjects who were enrolled in Nested Registry 3 under the IDE, including those enrolled under the continued access protocol.
Sample Size All living subjects
Data Collection The safety and effectiveness endpoints include all-cause mortality, all stroke, moderate or severe obstruction (defined as Doppler Velocity Index [DVI] < 0.25), or moderate or severe paravalvular leak (through 1 year only); all-cause mortality; all stroke or transient ischemic attack (TIA); all-cause mortality or major stroke; all stroke, major vascular complication, or aortic valve reintervention; New York Heart Association (NYHA) classification (additional data point at 6 months); change in 6-minute walk distance (6MWD) from baseline (through 1 year only); echocardiographic assessment of valve performance; clinical improvement per quality of life (QoL) instrument Kansas City Cardiomyopathy Questionnaire (KCCQ); and index hospitalization length of stay.
Follow-up Visits and Length of Follow-up 5 years

All subjects are followed at discharge or 7 days, whichever comes first, 30 days, 1 year, and annually thereafter through 5 years post procedure.

Continued f/u of the premarket cohort Schedule

Report Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
one year report 10/08/2016 10/06/2016 On Time
two year report 09/12/2017 09/12/2017 On Time
three year report 09/12/2018 09/11/2018 On Time
four year report 09/12/2019 09/06/2019 On Time
five year report 09/12/2020 09/10/2020 On Time
final report 09/12/2021 03/31/2021 On Time

Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources